Progressive liver injury and increased mortality risk in COVID-19 patients: A retrospective cohort study in China

Figure 3 Cumulative incidence of in-hospital mortality of patients with coronavirus disease 2019, stratified by liver disease indicators or hepatoprotective drugs. A-F: Shadows indicate the 95% confidence intervals of the corresponding estimates: Stages of on-admission liver injury (A), stages of cumulative liver injury (B), on-admission alanine aminotransferase (C), on-admission aspartate aminotransferase (D), on-admission total bilirubin (E), and hepatoprotective drug uses in patients with abnormal liver function (F). LB: Liver biochemistry; LBA: Liver biochemical abnormality; ALI: Acute liver injury; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; TBIL: Total bilirubin; HPD: Hepatoprotective drugs.